In terms of tumors, N4BP3 is able to promote the expression of STAT2 by interacting with KAT3B, thereby promoting the angiogenesis in hepatocellular carcinoma, making N4BP3 a potential therapeutic target for hepatocellular carcinoma [23]. Here, EP300 is linked to hepatocellular carcinoma.